Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 14

ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections

October 7, 2024

By Paul Feuerstadt, MD
Carl V. Crawford, MD

Opinion

Video

Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).

EP: 1.Epidemiology of C. difficile Infections in the US

EP: 2.Recurrence of C. Difficile Infections

EP: 3.Risk Factors for C. difficile Infections

EP: 4.Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors

EP: 5.Diagnostic Tests for C. difficile Infections

EP: 6.Treatment Guidelines for C. difficile Infection

EP: 7.Factors Contributing to C. difficile Infection Recurrence

EP: 8.Managing C. difficile Infections in the Clinic

EP: 9.Contribution of Unnecessary and Prolonged Antibiotic Use to Recurrent C. difficile Infections

EP: 10.Fecal Microbiota Transplantation for C. difficile Infections

EP: 11.Recent Fecal Microbiota Transplant Approvals for C. difficile Infections

EP: 12.Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice

EP: 13.Data on Fecal Microbiota, Live-JSLM (RBL) for C. difficile Infections

Now Viewing

EP: 14.ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections

EP: 15.Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens

EP: 16.Utilization of Fecal Microbiota Transplant Products in Clinical Practice

EP: 17.Physicians’ Use of Fecal Microbiota Transplant for Recurrent C. difficile Infections

EP: 18.Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

Video content above is prompted by the following:

Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Comparing the two clinical trials, what were some significant differences between them?